REGENXBIO Inc
For the period ended Dec 31, 2024. Filed Mar 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 13, 2025
RGNX$8.07+5.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Exhibit Index
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description | Form | ExhibitNumber | Filing Date | Filed orFurnishedHerewith |
| 1.1 | Sales Agreement dated December 9, 2024 between the Registrant and Leerink Partners LLC | 8-K | 1.1 | 12/9/24 | |
| 3.1 | Restated Certificate of Incorporation | 8-K | 3.1 | 6/7/21 | |
| 3.2 | Amended and Restated Bylaws | 8-K | 3.2 | 9/22/15 | |
| 4.1 | Specimen stock certificate evidencing the shares of common stock | S-1 | 4.1 | 8/17/15 | |
| 4.2 | Description of Securities | X | |||
| 4.3 | Form of Pre-funded Warrant | 8-K | 4.1 | 3/11/24 | |
| 10.1 | Form of Indemnity Agreement for directors and officers | S-1 | 10.1 | 8/17/15 | |
| 10.2* | 2014 Stock Plan, as amended | S-1 | 10.2 | 8/17/15 | |
| 10.3* | 2015 Equity Incentive Plan | S-1/A | 10.3 | 9/15/15 | |
| 10.4* | Form of Restricted Stock Unit Award Agreement for the 2015 Equity Incentive Plan | 10-K | 10.4 | 3/1/21 | |
| 10.5* | Form of Stock Option Award Agreement for the 2015 Equity Incentive Plan | 10-K | 10.5 | 3/1/21 | |
| 10.6* | 2015 Employee Stock Purchase Plan | S-1/A | 10.4 | 9/8/15 | |
| 10.7* | Employment Agreement effective as of July 1, 2024 between the Registrant and Curran Simpson | 10-Q | 10.1 | 8/1/24 | |
| 10.8* | Form of Employment Agreement for Executive Vice Presidents | 10-K | 10.9 | 2/27/24 | |
| 10.9* | Consulting and Employment Separation Agreement effective as of July 1, 2024 between the Registration and Kenneth T. Mills | 10-Q | 10.2 | 8/1/24 | |
| 10.10* | Employment Separation Agreement effective as of September 21, 2024 between the Registrant and Vittal Vasista | 10-Q | 10.1 | 11/6/24 | |
| 10.11* | Consulting Agreement effective as of September 21, 2024 between the Registrant and Vittal Vasista | 10-Q | 10.2 | 11/6/24 | |
| 10.12* | Compensation Program for Non-Employee Directors | 10-Q | 10.1 | 8/3/22 | |
| 10.13* | Management Cash Incentive Plan | S-1 | 10.29 | 8/17/15 | |
| 10.14† | License Agreement effective February 24, 2009 between the Registrant and The Trustees of the University of Pennsylvania | S-1/A | 10.9 | 9/15/15 | |
| 10.15† | First Amendment to License Agreement dated March 6, 2009 between the Registrant and The Trustees of the University of Pennsylvania | S-1 | 10.10 | 8/17/15 | |
| 10.16† | Second Amendment to License Agreement effective September 9, 2014 between the Registrant and The Trustees of the University of Pennsylvania | S-1/A | 10.11 | 9/15/15 | |
| 10.17† | Third Amendment to License Agreement effective April 29, 2016 between the Registrant and The Trustees of the University of Pennsylvania | 10-Q/A | 10.36 | 12/23/16 | |
| 10.18† | Fourth Amendment to License Agreement effective April 4, 2019 between the Registrant and The Trustees of the University of Pennsylvania | 10-Q | 10.2 | 5/7/19 | |
| Incorporated by Reference | ||||
|---|---|---|---|---|
| ExhibitNumber · Description · Form · ExhibitNumber · Filing Date · Filed orFurnishedHerewith | ||||
| 10.19† | Fifth Amendment to License Agreement effective September 11, 2020 between the Registrant and The Trustees of the University of Pennsylvania | 10-Q | 10.2 | 11/4/20 |
| 10.20† | Letter Agreement dated March 21, 2022 between the Company and the Trustees of the University of Pennsylvania | 10-Q | 10.1 | 5/4/22 |
| 10.21† | License Agreement dated March 6, 2009 between the Registrant and SmithKline Beecham Corporation d/b/a GlaxoSmithKline | S-1/A | 10.12 | 9/15/15 |
| 10.22 | Amendment to License Agreement dated April 15, 2009 between the Registrant and SmithKline Beecham Corporation d/b/a GlaxoSmithKline | S-1 | 10.13 | 8/17/15 |
| 10.23† | License Agreement dated March 21, 2014 between the Registrant and AveXis, Inc. | S-1/A | 10.16 | 9/15/15 |
| 10.24† | First Amendment to License Agreement dated January 8, 2018 between the Registrant and AveXis, Inc. | 10-K | 10.24 | 3/6/18 |
| 10.25† | Collaboration and License Agreement dated September 10, 2021 between the Registrant and AbbVie Global Enterprises Ltd. | 10-Q | 10.1 | 11/2/21 |
| 10.26 | Lease dated March 6, 2015 between the Registrant and BMR-Medical Center Drive LLC | S-1 | 10.26 | 8/17/15 |
| 10.27 | First Amendment to Lease dated September 30, 2015 between the Registrant and BMR-Medical Center Drive LLC | 10-K | 10.31 | 3/3/16 |
| 10.28 | Second Amendment to Lease dated November 23, 2015 between the Registrant and BMR-Medical Center Drive LLC | 10-K | 10.32 | 3/3/16 |
| 10.29 | Third Amendment to Lease dated July 21, 2017 between the Registrant and BMR-Medical Center Drive LLC | 10-Q | 10.1 | 8/8/17 |
| 10.30 | Fourth Amendment to Lease dated April 20, 2018 between the Registrant and BMR-Medical Center Drive LLC | 10-Q | 10.1 | 5/8/18 |
| 10.31 | Fifth Amendment to Lease dated October 30, 2020 between the Registrant and ARE-Maryland No. 45, LLC, as successor in interest to BMR-Medical Center Drive LLC | 10-Q | 10.3 | 11/4/20 |
| 10.32 | Lease dated November 1, 2018 between the Registrant and ARE-Maryland No. 24, LLC | 10-Q | 10.1 | 11/7/18 |
| 10.33 | Letter Agreement to Lease dated April 12, 2019 between the Registrant and ARE-Maryland No. 24, LLC | 10-Q | 10.3 | 5/7/19 |
| 10.34 | First Amendment to Lease dated April 23, 2019 between the Registrant and ARE-Maryland No. 24, LLC | 10-Q | 10.4 | 5/7/19 |
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description | Form | ExhibitNumber | Filing Date | Filed orFurnishedHerewith |
| 10.35 | Second Amendment to Lease dated November 4, 2019 between the Registrant and ARE-Maryland No. 24, LLC | 10-Q | 10.1 | 11/5/19 | |
| 10.36 | Third Amendment to Lease dated October 30, 2020 between the Registrant and ARE-Maryland No. 24, LLC | 10-Q | 10.4 | 11/4/20 | |
| 10.37† | Royalty Purchase Agreement dated December 22, 2020 between the Registrant and entities managed by Healthcare Royalty Management, LLC | 10-K | 10.42 | 3/1/21 | |
| 19.1 | Insider Trading Policy | X | |||
| 21.1 | Subsidiaries of the Registrant | X | |||
| 23.1 | Consent of PricewaterhouseCoopers LLP, independent registered accounting firm | X | |||
| 31.1 | Certification of the Chief Executive Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002 | X | |||
| 31.2 | Certification of the Chief Financial Officer as required by Section 302 of the Sarbanes-Oxley Act of 2002 | X | |||
| 32.1 | Certifications of the Chief Executive Officer and Chief Financial Officer as required by 18 U.S.C. 1350 | X | |||
| 97.1 | Compensation Clawback Policy | 10-K | 97.1 | 2/27/24 | |
| 101 | The following materials from the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets(ii) Consolidated Statements of Operations and Comprehensive Loss(iii) Consolidated Statements of Stockholders’ Equity(iv) Consolidated Statements of Cash Flows(v) Notes to Consolidated Financial Statements | X | |||
| 104 | The cover page from the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 formatted in Inline XBRL (included in Exhibit 101) | ||||
- Management contract or compensatory plan or arrangement.
† Portions of this exhibit have been omitted.
The certifications attached as Exhibit 32.1 that accompany this Annual Report on Form 10-K are not deemed filed with the SEC and are not to be incorporated by reference into any filing of REGENXBIO Inc. under the Securities Act or the Exchange Act, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.